HER2 expression variability between primary gastric cancers and corresponding lymph node metastases

Hepato-Gastroenterology

Volumn 62, Issue 137, 2015, Pages 231-233

  Qiu, Zhejun ^a   Sun, Weidong ^a   Zhou, Chengzhong ^a   Zhang, Jiandong ^a  

^a Department of Hematology and Oncology and Gastroenterology Ningbo PLA 113 Hospital   (China)

Author keywords

Discordance; Gastric cancer; HER2; Lymph node metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER STAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STOMACH CANCER; BIOPSY; CHEMISTRY; GASTRECTOMY; LYMPH NODE; LYMPH NODE DISSECTION; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; STOMACH NEOPLASMS; UPREGULATION;

AGED; BIOPSY; FEMALE; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84928530743     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge14692     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Van Ness M, Gregg J, Wang J and Chen M: Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine. J Gastrointest Oncol 2012; 3:243-251.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697,2010.
4. Jorgensen JT: Targeted HER2 treatment in advanced gastric cancer. Oncology 2010; 78: 26-33.
5. Sobin LH, Wittekind CH: International Union Against Cancer (UICC) TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss 2002.
6. Lauren P: The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
7. Hamilton SR, Aaltonen LA: World Health Organization and International Agency for Research on Cancer: Pathology and genetics of tumours of the digestive system, Lyon: IARC Press, 2000.
8. Carlsson J, Nordgren H, Sjostrom J, et al: HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004; 90: 2344-2348.
9. Wei Q, Chen L, Sheng L, Nordgren H, Wester K and Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 2007; 31:493-499.
10. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
11. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
12. Pagni F, Zannella S, Ronchi S, Garanzini C and Leone BE: HER2 status of gastric carcinoma and corresponding lymph node metastasis. Pathol Oncol Res 2013; 19:103-109.
13. Kaptain S, Tan LK and Chen B: Her-2/neu and breast cancer. Diagn Mol Pathol 10:139-152,2001.
14. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD and Sinicrope FA: HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 2004; 108: 540-548.
15. Marx AH, Tharun L, Muth J, et al: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009; 40: 769-777.
16. Bozzetti C, Negri FV, Lagrasta CA, et al: Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104:1372-1376.
17. Sheng WQ, Huang D, Ying JM, et al: HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 2013; 24: 2360-2364.
18. Mizutani T, Onda M, Tokunaga A, Yamanaka N and Sugisaki Y: Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993; 72: 2083-2088.
19. Janjigian YY, Werner D, Pauligk C, et al: Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012;23:2656-2662.
20. Kulig J, Kolodziejczyk P, Kulig P and Legutko J: Targeted therapy for gastric cancer - current status. J Oncol Pharm Pract 2012; 19: 75-81.
21. Kim KC, Koh YW, Chang HM, et al: Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18:2833-2840.
22. Simon R, Nocito A, Hubscher T, et al: Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93:1141-1146.
23. Sauter G, Moch H, Moore D, et al: Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993; 53:2199-2203.
24. Kim SY, Kim HP, Kim YJ, et al: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32:89-95.
25. Tanner M, Hollmen M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278.
26. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N and Kitano S: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005; 27: 681-685.
27. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007; 59: 795-805.
28. Kim MA, Lee HJ, Yang HK, Bang YJ and Kim WH: Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59:822-831.
29. Yu GZ, Chen Y and Wang JJ: Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009; 135:1331-1339.